Sinopharm Group Co. Ltd.
SHTDYOTCHealthcare● Active
$10.90
+$0.02(+0.18%)
Market Cap$6.8B
P/E Ratio—
52W High$14.87
52W Low$10.57
Sinopharm Group Co. Ltd. (SHTDY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SHTDY · earnings · updated Jun 10, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$0.83
Revenue
$40.57B
Est. $40.57B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
SHTDY reports quarterly as a OTC-listed Medical - Distribution company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 23, 2026 | — | $0.83 | — | $40.57B | $40.57B | +0.0% |
| — Q3 FY2025 | Aug 28, 2025 | — | $0.77 | — | $39.89B | — | — |
| ◌ Q2 FY2025 | Apr 25, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 21, 2025 | — | — | — | — | $150.1B | — |
| ◌ Q4 FY2024 | Oct 25, 2024 | — | — | — | — | — | — |
| — Q3 FY2024 | Aug 23, 2024 | — | $0.10 | — | $20.29B | — | — |
| — Q2 FY2024 | Apr 26, 2024 | — | $0.06 | — | $20.36B | — | — |
| — Q1 FY2024 | Mar 22, 2024 | — | $0.09 | — | $19.84B | — | — |
Q2 FY2026
Apr 23, 2026
EPS Actual
$0.83
EPS Est.
—
EPS Surpr.
—
Revenue
$40.57B
Q3 FY2025
Aug 28, 2025
EPS Actual
$0.77
EPS Est.
—
EPS Surpr.
—
Revenue
$39.89B
Q2 FY2025
Apr 25, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 21, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 25, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 23, 2024
EPS Actual
$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$20.29B
Q2 FY2024
Apr 26, 2024
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$20.36B
Q1 FY2024
Mar 22, 2024
EPS Actual
$0.09
EPS Est.
—
EPS Surpr.
—
Revenue
$19.84B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $284B | $284B | $284B | 1 |
| Q3 FY2025 | $286B | $286B | $286B | 1 |
| Q2 FY2025 | $144B | $144B | $144B | 1 |
| Q1 FY2025 | $142B | $142B | $142B | 1 |
| Q4 FY2024 | $142B | $142B | $142B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 23, 2026 | — | $12.64 | $12.41 | -1.82% |
| — Q3 FY2025 | Aug 28, 2025 | — | $12.04 | $11.91 | -1.08% |
| — Q3 FY2024 | Aug 23, 2024 | — | $11.86 | $11.86 | +0.00% |
| — Q2 FY2024 | Apr 26, 2024 | — | $13.88 | $13.74 | -1.01% |
| — Q1 FY2024 | Mar 22, 2024 | — | $13.32 | $13.11 | -1.58% |
| — Q4 FY2023 | Dec 31, 2023 | — | $13.05 | $12.83 | -1.69% |
| — Q2 FY2023 | Jun 30, 2023 | — | $15.37 | $15.55 | +1.17% |
| — Q1 FY2023 | Mar 31, 2023 | — | $14.64 | $14.89 | +1.71% |
Q2 FY2026-1.82%
Report Date
Apr 23, 2026
EPS Beat/Miss
—
Price Before
$12.64
Price After
$12.41
Q3 FY2025-1.08%
Report Date
Aug 28, 2025
EPS Beat/Miss
—
Price Before
$12.04
Price After
$11.91
Q3 FY2024+0.00%
Report Date
Aug 23, 2024
EPS Beat/Miss
—
Price Before
$11.86
Price After
$11.86
Q2 FY2024-1.01%
Report Date
Apr 26, 2024
EPS Beat/Miss
—
Price Before
$13.88
Price After
$13.74
Q1 FY2024-1.58%
Report Date
Mar 22, 2024
EPS Beat/Miss
—
Price Before
$13.32
Price After
$13.11
Q4 FY2023-1.69%
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
$13.05
Price After
$12.83
Q2 FY2023+1.17%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$15.37
Price After
$15.55
Q1 FY2023+1.71%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$14.64
Price After
$14.89
Beat Rate0 / 8 quarters
Largest Move-1.82% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SHTDY ends December
Sinopharm Group Co. Ltd. (SHTDY) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $0.83 (in line with the analyst consensus of —).
Each quarter, investors track SHTDY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SHTDY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SHTDY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SHTDY earnings · 4 questionsSinopharm Group Co. Ltd.'s next earnings report is expected around TBD. SHTDY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SHTDY historically reports after market close (AMC).
SHTDY earnings datewhen is SHTDY earningsSHTDY next earnings datewhen does SHTDY report earningsSHTDY earnings calendar
▸ Source: FMP · Sinopharm Group Co. Ltd. SEC filings · US GAAP · Sinopharm Group Co. Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026